HK1222563A1 - 药物组合物、制备及其用途 - Google Patents

药物组合物、制备及其用途 Download PDF

Info

Publication number
HK1222563A1
HK1222563A1 HK16110781.4A HK16110781A HK1222563A1 HK 1222563 A1 HK1222563 A1 HK 1222563A1 HK 16110781 A HK16110781 A HK 16110781A HK 1222563 A1 HK1222563 A1 HK 1222563A1
Authority
HK
Hong Kong
Prior art keywords
interest
compound
nanoparticle
pharmaceutical composition
subject
Prior art date
Application number
HK16110781.4A
Other languages
English (en)
Chinese (zh)
Inventor
Agnès Pottier
Laurent Levy
Marie-Edith MEYRE
Audrey DARMON
Matthieu Germain
Original Assignee
Curadigm Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curadigm Sas filed Critical Curadigm Sas
Publication of HK1222563A1 publication Critical patent/HK1222563A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16110781.4A 2013-05-30 2014-05-30 药物组合物、制备及其用途 HK1222563A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361828794P 2013-05-30 2013-05-30
EP13305712 2013-05-30
EP13305712.5 2013-05-30
US61/828,794 2013-05-30
PCT/EP2014/061296 WO2014191569A1 (en) 2013-05-30 2014-05-30 Pharmaceutical composition, preparation and uses thereof

Publications (1)

Publication Number Publication Date
HK1222563A1 true HK1222563A1 (zh) 2017-07-07

Family

ID=48656009

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16110781.4A HK1222563A1 (zh) 2013-05-30 2014-05-30 药物组合物、制备及其用途

Country Status (17)

Country Link
US (2) US10413509B2 (enExample)
EP (1) EP3003288A1 (enExample)
JP (1) JP6387400B2 (enExample)
KR (1) KR102245421B1 (enExample)
CN (2) CN105407878A (enExample)
AU (1) AU2014273043B2 (enExample)
BR (1) BR112015029853A2 (enExample)
CA (1) CA2913023C (enExample)
EA (1) EA038671B1 (enExample)
HK (1) HK1222563A1 (enExample)
MA (1) MA38687A1 (enExample)
MX (1) MX376269B (enExample)
NZ (1) NZ714273A (enExample)
SG (1) SG11201509436TA (enExample)
UA (1) UA116380C2 (enExample)
WO (1) WO2014191569A1 (enExample)
ZA (1) ZA201509307B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104093401B (zh) 2011-12-16 2018-06-29 纳米生物技术公司 包含金属材料和氧化铪材料的纳米粒子、其制备和用途
CN105407878A (zh) 2013-05-30 2016-03-16 纳米生物技术公司 药物组合物、制备及其用途
TW201628610A (zh) 2014-11-25 2016-08-16 奈諾生技公司 醫藥組合物、其製備及其用途
DK3229843T3 (da) * 2014-11-25 2020-03-09 Curadigm Sas Farmaceutisk sammensætning, præparat og anvendelser deraf
JP6836510B2 (ja) * 2014-11-25 2021-03-03 キュラディグム・エスアエスＣｕｒａｄｉｇｍ Ｓａｓ 少なくとも２つの異なるナノ粒子と医薬化合物とを組み合わせた医薬組成物、その調製及び使用
US10765632B2 (en) 2014-11-25 2020-09-08 Curadigm Sas Methods of improving delivery of compounds for therapy, prophylaxis or diagnosis
US10792366B2 (en) * 2015-02-19 2020-10-06 Carnegie Mellon University Methods to reduce toxicities and to improve bioavailabilities of nanodrugs
EA201792560A1 (ru) 2015-05-28 2018-06-29 Нанобиотикс Наночастицы для применения в качестве терапевтической вакцины
CN105055447B (zh) * 2015-06-23 2018-03-13 中南大学湘雅二医院 氧化铁纳米颗粒用于制备改善厄洛替尼耐药性药物的应用
US20210260187A1 (en) * 2018-06-29 2021-08-26 North Carolina State University In situ sprayed bioresponsive immunotherapeutic gel for post-surgical treatment
CN108969757B (zh) * 2018-07-11 2021-07-27 浙江大学 负载microRNA的氧化铈纳米复合水凝胶及制备方法和应用
CN110498607B (zh) * 2019-08-21 2022-03-08 中国科学院上海硅酸盐研究所 一种多功能钙硅基稀土掺杂的生物活性粉体及其制备方法和应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4280918A (en) * 1980-03-10 1981-07-28 International Business Machines Corporation Magnetic particle dispersions
US20030186869A1 (en) * 1990-05-14 2003-10-02 George Poiani Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor
US6686332B1 (en) * 1993-10-15 2004-02-03 Xoma Corporation Method of treating depressed reticuloendothelial system function
GB9509321D0 (en) 1995-05-09 1995-06-28 Zylepsis Ltd Methods of and substances for inhibiting oxidative enzymes
US6160006A (en) 1996-10-18 2000-12-12 Wayne State University 6',7'-dihydroxybergamottin, a cytochrome P450 inhibitor in grapefruit
JPH10120597A (ja) * 1996-10-22 1998-05-12 Eiken Chem Co Ltd リンパ節高集積性コロイド粒子
DE69819519T2 (de) 1997-08-19 2004-09-23 Warner-Lambert Co. Llc Bergamottin enthaltende zusammensetzungen zur erhöhung der oralen bioverfügbarkeit von pharmazeutika
US20040166060A1 (en) * 2000-06-16 2004-08-26 Sloan Kettering Institute For Cancer Research Liposomal encapsulation of alpha particle emittors and uses thereof
AU2001270385B2 (en) * 2000-06-30 2006-05-25 Talon Therapeutics, Inc. Liposomal antineoplastic drugs and uses thereof
US8178123B2 (en) 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
US20050090732A1 (en) * 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
JP5513708B2 (ja) * 2003-12-22 2014-06-04 ブラッコ・シュイス・ソシエテ・アノニム 造影イメージング用の気体封入マイクロベシクル・アセンブリー
WO2005086639A2 (en) 2004-02-10 2005-09-22 Barnes-Jewish Hospital Improved efficacy and safety of targeted particulate agents with decoy systems
US20060264804A1 (en) 2005-04-07 2006-11-23 Yoram Karmon Device and kit for delivery of encapsulated substances and methods of use thereof
WO2006127962A2 (en) * 2005-05-25 2006-11-30 Becton, Dickinson And Comapny Particulate formulations for intradermal delivery of biologically active agents
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
US20090130050A1 (en) 2006-03-24 2009-05-21 Toto Ltd. Titanium Oxide Composite Particles, Dispersion Liquid Thereof, and Process for Producing Them
JP2009536151A (ja) * 2006-03-30 2009-10-08 富士フイルム株式会社 ナノ粒子
US20090181076A1 (en) 2006-05-04 2009-07-16 University Of South Australia Drug Release From Nanoparticle-Coated Capsules
CN101795671A (zh) 2007-08-21 2010-08-04 阿尔扎公司 用于体内施用硼酸化合物的脂质体组合物
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
WO2009081287A2 (en) * 2007-12-21 2009-07-02 University Of Guelph Polysaccharide nanoparticles
US9403789B2 (en) 2008-02-21 2016-08-02 Sequoia Pharmaceuticals, Inc. Benzofuran-containing amino acid inhibitors of cytochrome P450
WO2009142754A1 (en) * 2008-05-22 2009-11-26 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dendritic conjugates and methods of use
EP2130553A1 (en) 2008-06-05 2009-12-09 Nanobiotix Inorganic nanoparticles of high density to destroy cells in-vivo
US20130023714A1 (en) * 2008-10-26 2013-01-24 Board Of Regents, The University Of Texas Systems Medical and Imaging Nanoclusters
EP2275137A1 (en) * 2009-07-10 2011-01-19 Nanobiotix Metallic nanoparticles, preparation and uses thereof
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
EP2660318A1 (en) * 2010-02-09 2013-11-06 Sangamo BioSciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
WO2011102407A1 (ja) 2010-02-17 2011-08-25 国立大学法人神戸大学 放射線治療剤
CN104784121A (zh) 2010-03-26 2015-07-22 阿布拉科斯生物科学有限公司 治疗肝细胞癌的方法
GB201009455D0 (en) * 2010-06-04 2010-07-21 King S College London Nanoparticles and their uses in molecular imaging
US9782342B2 (en) 2010-10-11 2017-10-10 Wichita State University Composite magnetic nanoparticle drug delivery system
EP3192800A1 (en) 2010-12-17 2017-07-19 Arrowhead Pharmaceuticals, Inc. Galactose cluster-pharmacokinetic modulator targeting moiety for sirna
EA024930B1 (ru) * 2011-01-31 2016-11-30 Нанобиотикс Системы доставки наночастиц, их получение и применение
WO2012104277A2 (en) 2011-01-31 2012-08-09 Nanobiotix Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles.
US20120237566A1 (en) * 2011-03-15 2012-09-20 Venture Isles, LLC Inhibiting stomach-acid release, reducing inflammation and preventing and treating cancer: compositions and methods of use
WO2013059295A2 (en) 2011-10-17 2013-04-25 Trustees Of Boston University Polymeric depots for localization of an agent to biological sites
CN102532154B (zh) 2012-01-11 2014-05-14 昆明医学院 隆萼当归线型呋喃香豆素化合物及其应用
WO2014039874A2 (en) 2012-09-07 2014-03-13 Carnegie Mellon University Methods and materials for reducing reticuloendothelial system clearance of particles from a subject
ITRM20120480A1 (it) 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
CN105407878A (zh) 2013-05-30 2016-03-16 纳米生物技术公司 药物组合物、制备及其用途
EP2886128A1 (en) 2013-12-20 2015-06-24 Nanobiotix Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
JP6836510B2 (ja) 2014-11-25 2021-03-03 キュラディグム・エスアエスＣｕｒａｄｉｇｍ Ｓａｓ 少なくとも２つの異なるナノ粒子と医薬化合物とを組み合わせた医薬組成物、その調製及び使用
TW201628610A (zh) 2014-11-25 2016-08-16 奈諾生技公司 醫藥組合物、其製備及其用途
US10765632B2 (en) 2014-11-25 2020-09-08 Curadigm Sas Methods of improving delivery of compounds for therapy, prophylaxis or diagnosis
MX2017006813A (es) 2014-11-25 2018-01-30 Nanobiotix Composicion farmaceutica, preparacion y usos de la misma.
DK3229843T3 (da) 2014-11-25 2020-03-09 Curadigm Sas Farmaceutisk sammensætning, præparat og anvendelser deraf

Also Published As

Publication number Publication date
CA2913023C (en) 2021-06-08
CN112107558A (zh) 2020-12-22
AU2014273043B2 (en) 2019-02-07
MA38687A1 (fr) 2017-12-29
KR102245421B1 (ko) 2021-04-29
SG11201509436TA (en) 2015-12-30
JP6387400B2 (ja) 2018-09-05
CN105407878A (zh) 2016-03-16
KR20160013212A (ko) 2016-02-03
EP3003288A1 (en) 2016-04-13
WO2014191569A1 (en) 2014-12-04
MX2015016456A (es) 2016-03-03
US20200009050A1 (en) 2020-01-09
ZA201509307B (en) 2017-04-26
CA2913023A1 (en) 2014-12-04
US10413509B2 (en) 2019-09-17
UA116380C2 (uk) 2018-03-12
JP2016522833A (ja) 2016-08-04
BR112015029853A2 (pt) 2017-07-25
EA201592279A1 (ru) 2016-06-30
NZ714273A (en) 2019-04-26
EA038671B1 (ru) 2021-10-01
US11357724B2 (en) 2022-06-14
MX376269B (es) 2025-03-07
AU2014273043A1 (en) 2015-12-03
US20160184225A1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
HK1222563A1 (zh) 药物组合物、制备及其用途
HK1245086A1 (zh) 处方药物组成及其制备和使用
EP4431155A3 (en) Pharmaceutical composition, preparation and uses thereof
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
WO2017042607A3 (en) Compositions comprising meloxicam-cyclodextrin inclusion complexes and methods of treating acute pain
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
CA2894891A1 (en) Boronic acid derivatives and therapeutic uses thereof
HK1218560A1 (zh) 组成与方法
NZ602557A (en) Solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
WO2013158680A3 (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
MX355330B (es) Formas cristalinas de compuestos terapeuticos y sus usos.
HK1212207A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
WO2014108846A3 (en) Soothing cosmetic composition based on salicylic acid
WO2011025286A3 (ko) 리포테이코익산 유래 당지질 및 이를 포함하는 조성물
WO2014058979A3 (en) Laquinimod for reducing thalamic damage in multiple sclerosis
GB2489382A (en) Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
SG10201907291QA (en) Monomethylfumarate prodrug compositions
WO2014064652A3 (en) Stable pharmaceutical composition of peginterferon alpha-2b
WO2014133811A3 (en) Compounds from invasive salvinias and methods of using the same
IN2013MU01177A (enExample)
WO2012168282A3 (en) Sunscreens with reduced whitening effect
EA032913B1 (ru) Препараты производных пиримидиндиона
NZ704342A (en) Compositions comprising spicamycin derivatives and methods of use thereof
HK1206649A1 (en) Method of treating acne
WO2012149295A3 (en) Methods of administering anatabine to treat autism spectrum disorders and seizure disorders